Bioventus Inc (FRA:4B8)
€ 11.95 -1.15 (-8.78%) Market Cap: 1.03 Bil Enterprise Value: 1.26 Bil PE Ratio: 18.34 PB Ratio: 4.38 GF Score: 45/100

Bioventus Inc at JPMorgan Healthcare Conference Transcript

Jan 14, 2026 / 05:45PM GMT
Dawit Ghebremedhin
J.P. Morgan Securities LLC - Analyst

Morning, everyone. Welcome. Thank you for joining us. My name is Dawit Ghebremedhin, I'm an associate on health care team at JPMorgan. And today, I have the pleasure of introducing the Bioventus team. Joining us today is CEO, Rob Claypoole; and CFO, Mark Singleton.

Just a quick reminder on format. This will be a 20-minute presentation followed by 20 minutes of Q&A. So please save any questions until the end of the presentation.

And with that, I'll pass it off to Rob. Thank you.

Robert Claypoole
Bioventus Inc - President, Chief Executive Officer, Director

All right. Thanks for the introduction, Dawit, and good morning, everyone. Appreciate you joining us today. At Bioventus, our mission is to help patients recover and live life to the fullest.

I'm entering my third year as CEO and over the next few minutes, I'd like to do two things. First, highlight the significant changes and the strong performance that we've driven over the past few years. And second, show you that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot